Aptinyx Inc.

CNS diseases


HBM contact: Dr Ivo Staijen, Dr Alexander Asam

Company status: public

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders. Aptinyx has a proven platform for discovering compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. The lead asset is undergoing two Phase 2 clinical trials in painful diabetic peripheral neuropathy as well as fibromyalgia.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171